Pediatric patients with ALL can expect therapies to help target their disease after they relapse, but experts are looking to combat the disease in the frontline before that.
Nirali N. Shah, MD, MHSc
Advertisement
Articles by Nirali N. Shah, MD, MHSc
Advertisement
Latest Updated Articles
Moving Therapies From the Relapse/Refractory Setting to the FrontlinePublished: September 20th 2019 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA OKs Subcutaneous Amivantamab Across All NSCLC Indications
2
Mobile Health Intervention Ups QOL in AYA Breast Cancer Survivors
3
FDA Approves Rucaparib in BRCA-Mutated Metastatic CRPC
4
T-DXd/Pertuzumab Combo Earns FDA Approval in Advanced HER2+ Breast Cancer
5